Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Insulin Therapy and Outcome of Coronavirus Disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression

Author(s): Timotius Ivan Hariyanto, Nata Pratama Hardjo Lugito, Theo Audi Yanto, Jeremia Immanuel Siregar and Andree Kurniawan*

Volume 22, Issue 5, 2022

Published on: 31 January, 2022

Page: [481 - 489] Pages: 9

DOI: 10.2174/1871530321666210709164925

Price: $65

Abstract

Background: Currently, the relationship between insulin therapy and COVID-19 outcome is not yet established. Our study aims to evaluate the possible association between insulin and the composite poor outcome of COVID-19.

Methods: We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until December 12th, 2020. All articles published on COVID-19 and insulin were retrieved. Statistical analysis was done using Review Manager 5.4 and Comprehensive Meta-Analysis version 3 software.

Results: Our pooled analysis showed that insulin use was associated with composite poor outcomes of COVID-19 [OR 2.06 (95% CI 1.70 – 2.48), p < 0.00001, I2 = 83%, random-effect modelling], and its subgroup which comprised of risk of COVID-19 [OR 1.70 (95% CI 1.40 – 2.08), p < 0.00001, I2 = 34%, random-effect modelling], severe COVID-19 [OR 2.30 (95% CI 1.60 – 3.30), p < 0.00001, I2 = 88%, random-effect modelling], and mortality [OR 2.14 (95% CI 1.47 – 3.10), p < 0.0001, I2 = 85%, random-effect modelling]. Meta-regression showed that the association was influenced by age (p = 0.008), but not by diabetes p = 0.423) and cardiovascular disease (p = 0.086).

Conclusion: Physicians should be more aware and take extra precautions with diabetes patients who use insulin therapy.

Keywords: Diabetes, medications, insulin, coronavirus, COVID-19, SARS-CoV-2.

« Previous Next »
Graphical Abstract

[1]
Kwenandar, F.; Japar, K.V.; Damay, V.; Hariyanto, T.I.; Tanaka, M.; Lugito, N.P.H.; Kurniawan, A. Coronavirus disease 2019 and cardiovascular system: A narrative review. Int. J. Cardiol. Heart Vasc., 2020, 29, 100557.
[http://dx.doi.org/10.1016/j.ijcha.2020.100557] [PMID: 32550259]
[2]
Hariyanto, T.I.; Kristine, E.; Jillian Hardi, C.; Kurniawan, A. Efficacy of lopinavir/ritonavir compared with standard care for treatment of coronavirus disease 2019 (covid-19): A systematic review. Infect. Disord. Drug Targets, 2021, 21(5), e27042118364.
[http://dx.doi.org/10.2174/1871526520666201029125725] [PMID: 33121422]
[3]
Hariyanto, T.I.; Kurniawan, A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr., 2020, 14(5), 1429-1430.
[http://dx.doi.org/10.1016/j.dsx.2020.07.044] [PMID: 32755846]
[4]
Hariyanto, T.I.; Kurniawan, A. Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Transfus. Apheresis Sci., 2020, 59(6), 102926.
[http://dx.doi.org/10.1016/j.transci.2020.102926] [PMID: 32893135]
[5]
Hariyanto, T.I.; Kurniawan, A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr., 2020, 14(5), 1463-1465.
[http://dx.doi.org/10.1016/j.dsx.2020.07.054] [PMID: 32771919]
[6]
Hariyanto, T.I.; Kurniawan, A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr., 2020, 14(6), 1613-1615.
[http://dx.doi.org/10.1016/j.dsx.2020.08.023] [PMID: 32882643]
[7]
Hariyanto, T.I.; Putri, C.; Situmeang, R.F.V.; Kurniawan, A. Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection. Eur. Arch. Psychiatry Clin. Neurosci., 2020, 1–3
[http://dx.doi.org/10.1007/s00406-020-01205-z] [PMID: 33104903]
[8]
Hariyanto, T.I.; Putri, C.; Arisa, J.; Situmeang, R.F.V.; Kurniawan, A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis. Arch. Gerontol. Geriatr., 2020, 93, 104299.
[http://dx.doi.org/10.1016/j.archger.2020.104299] [PMID: 33285424]
[9]
Singh, A.K.; Khunti, K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. Diabetes Res. Clin. Pract., 2020, 165, 108266.
[http://dx.doi.org/10.1016/j.diabres.2020.108266] [PMID: 32533989]
[10]
Zhu, L.; She, Z.G.; Cheng, X.; Qin, J.J.; Zhang, X.J.; Cai, J.; Lei, F.; Wang, H.; Xie, J.; Wang, W.; Li, H.; Zhang, P.; Song, X.; Chen, X.; Xiang, M.; Zhang, C.; Bai, L.; Xiang, D.; Chen, M.M.; Liu, Y.; Yan, Y.; Liu, M.; Mao, W.; Zou, J.; Liu, L.; Chen, G.; Luo, P.; Xiao, B.; Zhang, C.; Zhang, Z.; Lu, Z.; Wang, J.; Lu, H.; Xia, X.; Wang, D.; Liao, X.; Peng, G.; Ye, P.; Yang, J.; Yuan, Y.; Huang, X.; Guo, J.; Zhang, B.H.; Li, H. Association of blood glucose control and outcomes in patients with covid-19 and pre-existing type 2 diabetes. Cell Metab., 2020, 31(6), 1068-1077.e3.
[http://dx.doi.org/10.1016/j.cmet.2020.04.021] [PMID: 32369736]
[11]
Hariyanto, T.I.; Kurniawan, A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes. Med., 2020, 19, 100290.
[http://dx.doi.org/10.1016/j.obmed.2020.100290] [PMID: 32844132]
[12]
Gupta, R.; Ghosh, A.; Singh, A.K.; Misra, A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab. Syndr., 2020, 14(3), 211-212.
[http://dx.doi.org/10.1016/j.dsx.2020.03.002] [PMID: 32172175]
[13]
Longo, M.; Caruso, P.; Maiorino, M.I.; Bellastella, G.; Giugliano, D.; Esposito, K. Treating type 2 diabetes in COVID-19 patients: The potential benefits of injective therapies. Cardiovasc. Diabetol., 2020, 19(1), 115.
[http://dx.doi.org/10.1186/s12933-020-01090-9] [PMID: 32698837]
[14]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7), e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[15]
Margulis, A.V.; Pladevall, M.; Riera-Guardia, N.; Varas-Lorenzo, C.; Hazell, L.; Berkman, N.D. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The newcastle-ottawa scale and the rti item bank. Clin Epidemiol., 2014, 6, 359-368.
[http://dx.doi.org/10.2147/CLEP.S66677]
[16]
Al Hayek, A.A.; Robert, A.A.; Matar, A.B.; Algarni, A.; Alkubedan, H.; Alharbi, T.; Al Amro, A.; Alrashidi, S.A.; Al Dawish, M. Risk factors for hospital admission among COVID-19 patients with diabetes. A study from Saudi Arabia. Saudi Med. J., 2020, 41(10), 1090-1097.
[http://dx.doi.org/10.15537/smj.2020.10.25419] [PMID: 33026050]
[17]
Ayed, M.; Borahmah, A.A.; Yazdani, A.; Sultan, A.; Mossad, A.; Rawdhan, H. Assessment of clinical characteristics and mortality-associated factors in COVID-19 Critical cases in Kuwait. Med. Princ. Pract., 2021, 30(2), 185-192.
[http://dx.doi.org/10.1159/000513047] [PMID: 33197912]
[18]
Cariou, B.; Hadjadj, S.; Wargny, M.; Pichelin, M.; Al-Salameh, A.; Allix, I.; Amadou, C.; Arnault, G.; Baudoux, F.; Bauduceau, B.; Borot, S.; Bourgeon-Ghittori, M.; Bourron, O.; Boutoille, D.; Cazenave-Roblot, F.; Chaumeil, C.; Cosson, E.; Coudol, S.; Darmon, P.; Disse, E.; Ducet-Boiffard, A.; Gaborit, B.; Joubert, M.; Kerlan, V.; Laviolle, B.; Marchand, L.; Meyer, L.; Potier, L.; Prevost, G.; Riveline, J.P.; Robert, R.; Saulnier, P.J.; Sultan, A.; Thébaut, J.F.; Thivolet, C.; Tramunt, B.; Vatier, C.; Roussel, R.; Gautier, J.F.; Gourdy, P. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study. Diabetologia, 2020, 63(8), 1500-1515.
[http://dx.doi.org/10.1007/s00125-020-05180-x] [PMID: 32472191]
[19]
Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; Zheng, L.; Huang, K. Clinical characteristics and outcomes of patients with diabetes and covid-19 in association with glucose-lowering medication. Diabetes Care, 2020, 43(7), 1399-1407.
[http://dx.doi.org/10.2337/dc20-0660] [PMID: 32409498]
[20]
Crouse, A; Grimes, T; Li, P; Might, M; Ovalle, F; Shalev, A. Metformin use is associated with reduced mortality in a diverse population with covid-19 and diabetes. medRxiv, 2020.
[21]
Dashti, H.T.; Bates, D.; Fiskio, J.M.; Roche, E.C.; Mora, S.; Demler, O. Clinical characteristics and severity of covid-19 disease in patients from boston area hospitals. medRxiv, 2020.
[22]
Dublin, S; Walker, R; Floyd, JS; Shortreed, SM; Fuller, S; Albertson-Junkans, L Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: A cohort study. Am. J. Hypertens., 2021, 34(4), 339-34.
[23]
Georges, JL; Gilles, FF; Cochet, H; Bertrand, A; De Tournemire, M; Monguillon, V Positive association of angiotensin ii receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to sars-cov-2 infection in patients hospitalized for suspected covid-19 pneumonia. medRxiv, 2020.
[24]
Giacomelli, A.; Ridolfo, A.L.; Milazzo, L.; Oreni, L.; Bernacchia, D.; Siano, M.; Bonazzetti, C.; Covizzi, A.; Schiuma, M.; Passerini, M.; Piscaglia, M.; Coen, M.; Gubertini, G.; Rizzardini, G.; Cogliati, C.; Brambilla, A.M.; Colombo, R.; Castelli, A.; Rech, R.; Riva, A.; Torre, A.; Meroni, L.; Rusconi, S.; Antinori, S.; Galli, M. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol. Res., 2020, 158, 104931.
[http://dx.doi.org/10.1016/j.phrs.2020.104931] [PMID: 32446978]
[25]
Khider, L.; Gendron, N.; Goudot, G.; Chocron, R.; Hauw-Berlemont, C.; Cheng, C.; Rivet, N.; Pere, H.; Roffe, A.; Clerc, S.; Lebeaux, D.; Debuc, B.; Veyer, D.; Rance, B.; Gaussem, P.; Bertil, S.; Badoual, C.; Juvin, P.; Planquette, B.; Messas, E.; Sanchez, O.; Hulot, J.S.; Diehl, J.L.; Mirault, T.; Smadja, D.M. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J. Thromb. Haemost., 2020, 18(9), 2391-2399.
[http://dx.doi.org/10.1111/jth.14968] [PMID: 32558198]
[26]
Maddaloni, E.; D’Onofrio, L.; Alessandri, F.; Mignogna, C.; Leto, G.; Coraggio, L.; Sterpetti, S.; Pascarella, G.; Mezzaroma, I.; Lichtner, M.; Pozzilli, P.; Agrò, F.E.; Rocco, M.; Pugliese, F.; Mastroianni, C.M.; Buzzetti, R. Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). Diabetes Res. Clin. Pract., 2020, 169, 108454.
[http://dx.doi.org/10.1016/j.diabres.2020.108454] [PMID: 32971157]
[27]
Mancia, G.; Rea, F.; Ludergnani, M.; Apolone, G.; Corrao, G. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N. Engl. J. Med., 2020, 382(25), 2431-2440.
[http://dx.doi.org/10.1056/NEJMoa2006923] [PMID: 32356627]
[28]
Nguyen, AB; Upadhyay, GA; Chung, B; Smith, B; Besser, SA; Johnson, J.A. Outcomes and cardiovascular comorbidities in a predominantly african-american population with covid-19. medRxiv, 2020.
[29]
Pérez-Belmonte, L.M.; Torres-Peña, J.D.; López-Carmona, M.D.; Ayala-Gutiérrez, M.M.; Fuentes-Jiménez, F.; Huerta, L.J.; Muñoz, J.A.; Rubio-Rivas, M.; Madrazo, M.; Garcia, M.G.; Montes, B.V.; Sola, J.F.; Ena, J.; Ferrer, R.G.; Pérez, C.M.; Ripper, C.J.; Lecumberri, J.J.N.; Acedo, I.E.A.; Canteli, S.P.; Cosío, S.F.; Martínez, F.A.; Rodríguez, B.C.; Pérez-Martínez, P.; Ramos-Rincón, J.M.; Gómez-Huelgas, R. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: A nationwide cohort study. BMC Med., 2020, 18(1), 359.
[http://dx.doi.org/10.1186/s12916-020-01832-2] [PMID: 33190637]
[30]
Poblador-Plou, B.; Carmona-Pírez, J.; Ioakeim-Skoufa, I.; Poncel-Falcó, A.; Bliek-Bueno, K.; Cano-Del Pozo, M.; Gimeno-Feliú, L.A.; González-Rubio, F.; Aza-Pascual-Salcedo, M.; Bandrés-Liso, A.C.; Díez-Manglano, J.; Marta-Moreno, J.; Mucherino, S.; Gimeno-Miguel, A.; Prados-Torres, A. Baseline chronic comorbidity and mortality in laboratory-confirmed covid-19 cases: Results from the precovid study in spain. Int. J. Environ. Res. Public Health, 2020, 17(14), 5171.
[http://dx.doi.org/10.3390/ijerph17145171] [PMID: 32709002]
[31]
Selçuk, M.; Çınar, T.; Keskin, M.; Çiçek, V.; Kılıç, Ş.; Kenan, B.; Doğan, S.; Asal, S.; Günay, N.; Yıldırım, E.; Keskin, Ü.; Orhan, A.L. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin. Exp. Hypertens., 2020, 42(8), 738-742.
[http://dx.doi.org/10.1080/10641963.2020.1783549] [PMID: 32569491]
[32]
Sourij, H.; Aziz, F.; Bräuer, A.; Ciardi, C.; Clodi, M.; Fasching, P. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes. Metab., 2020.
[http://dx.doi.org/10.1111/dom.14256] [PMID: 33200501]
[33]
Vila-Corcoles, A.; Satue-Gracia, E.; Ochoa-Gondar, O.; Torrente-Fraga, C.; Gomez-Bertomeu, F.; Vila-Rovira, A.; Hospital-Guardiola, I.; de Diego-Cabanes, C.; Bejarano-Romero, F.; Rovira-Veciana, D.; Basora-Gallisa, J. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. J. Clin. Hypertens. (Greenwich), 2020, 22(8), 1379-1388.
[http://dx.doi.org/10.1111/jch.13948] [PMID: 32710674]
[34]
Wu, J.; Huang, J.; Zhu, G.; Wang, Q.; Lv, Q.; Huang, Y.; Yu, Y.; Si, X.; Yi, H.; Wang, C.; Liu, Y.; Xiao, H.; Zhou, Q.; Liu, X.; Yang, D.; Guan, X.; Li, Y.; Peng, S.; Sung, J.; Xiao, H. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: A retrospective cohort study. BMJ Open Diabetes Res. Care, 2020, 8(1), e001476.
[http://dx.doi.org/10.1136/bmjdrc-2020-001476] [PMID: 32503812]
[35]
Yan, H.; Valdes, A.M.; Vijay, A.; Wang, S.; Liang, L.; Yang, S.; Wang, H.; Tan, X.; Du, J.; Jin, S.; Huang, K.; Jiang, F.; Zhang, S.; Zheng, N.; Hu, Y.; Cai, T.; Aithal, G.P. Role of drugs used for chronic disease management on susceptibility and severity of covid-19: A large case-control study. Clin. Pharmacol. Ther., 2020, 108(6), 1185-1194.
[http://dx.doi.org/10.1002/cpt.2047] [PMID: 32910830]
[36]
Yan, Y.; Yang, Y.; Wang, F.; Ren, H.; Zhang, S.; Shi, X.; Yu, X.; Dong, K. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res. Care, 2020, 8(1), e001343.
[http://dx.doi.org/10.1136/bmjdrc-2020-001343] [PMID: 32345579]
[37]
Yu, B; Li, C; Sun, Y; Wang, DW Insulin treatment is associated with increased mortality in patients with covid-19 and type 2 diabetes. Cell Metab., 2020, S1550-4131(20), 30641-30647.
[38]
Zhang, N.; Wang, C.; Zhu, F.; Mao, H.; Bai, P.; Chen, L.L.; Zeng, T.; Peng, M.M.; Qiu, K.L.; Wang, Y.; Yu, M.; Xu, S.; Zhao, J.; Li, N.; Zhou, M. Risk factors for poor outcomes of diabetes patients with covid-19: A single-center, retrospective study in early outbreak in china. Front. Endocrinol. (Lausanne), 2020, 11, 571037.
[http://dx.doi.org/10.3389/fendo.2020.571037] [PMID: 33071977]
[39]
Zhang, Q.; Wei, Y.; Chen, M.; Wan, Q.; Chen, X. Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes. J. Diabetes Complications, 2020, 34(10), 107666.
[http://dx.doi.org/10.1016/j.jdiacomp.2020.107666] [PMID: 32636061]
[40]
Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R.H., Jr; Probstfield, J.L.; Simons-Morton, D.G.; Friedewald, W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2545-2559.
[http://dx.doi.org/10.1056/NEJMoa0802743] [PMID: 18539917]
[41]
Khunti, K.; Alsifri, S.; Aronson, R.; Cigrovski Berković, M.; Enters-Weijnen, C.; Forsén, T.; Galstyan, G.; Geelhoed-Duijvestijn, P.; Goldfracht, M.; Gydesen, H.; Kapur, R.; Lalic, N.; Ludvik, B.; Moberg, E.; Pedersen-Bjergaard, U.; Ramachandran, A. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: The global HAT study. Diabetes Obes. Metab., 2016, 18(9), 907-915.
[http://dx.doi.org/10.1111/dom.12689] [PMID: 27161418]
[42]
McCoy, R.G.; Van Houten, H.K.; Ziegenfuss, J.Y.; Shah, N.D.; Wermers, R.A.; Smith, S.A. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care, 2012, 35(9), 1897-1901.
[http://dx.doi.org/10.2337/dc11-2054] [PMID: 22699297]
[43]
Akirov, A.; Grossman, A.; Shochat, T.; Shimon, I. Mortality among hospitalized patients with hypoglycemia: Insulin related and noninsulin related. J. Clin. Endocrinol. Metab., 2017, 102(2), 416-424.
[http://dx.doi.org/10.1210/jc.2016-2653] [PMID: 27854553]
[44]
Yun, J.S.; Park, Y.M.; Han, K.; Cha, S.A.; Ahn, Y.B.; Ko, S.H. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: A nationwide population-based cohort study. Cardiovasc. Diabetol., 2019, 18(1), 103.
[http://dx.doi.org/10.1186/s12933-019-0909-y] [PMID: 31412855]
[45]
Yang, J.K.; Feng, Y.; Yuan, M.Y.; Yuan, S.Y.; Fu, H.J.; Wu, B.Y.; Sun, G.Z.; Yang, G.R.; Zhang, X.L.; Wang, L.; Xu, X.; Xu, X.P.; Chan, J.C. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med., 2006, 23(6), 623-628.
[http://dx.doi.org/10.1111/j.1464-5491.2006.01861.x] [PMID: 16759303]
[46]
Filgueiras, L.R.; Capelozzi, V.L.; Martins, J.O.; Jancar, S. Sepsis-induced lung inflammation is modulated by insulin. BMC Pulm. Med., 2014, 14, 177.
[http://dx.doi.org/10.1186/1471-2466-14-177] [PMID: 25398720]
[47]
Lim, S.; Bae, J.H.; Kwon, H.S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol., 2021, 17(1), 11-30.
[http://dx.doi.org/10.1038/s41574-020-00435-4] [PMID: 33188364]
[48]
Pal, R.; Bhadada, S.K. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab. Syndr., 2020, 14(4), 513-517.
[http://dx.doi.org/10.1016/j.dsx.2020.04.049] [PMID: 32388331]
[49]
Mavridis, G.; Souliou, E.; Diza, E.; Symeonidis, G.; Pastore, F.; Vassiliou, A.M.; Karamitsos, D. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis., 2008, 18(7), 471-476.
[http://dx.doi.org/10.1016/j.numecd.2007.02.013] [PMID: 17976964]
[50]
Leisman, D.E.; Ronner, L.; Pinotti, R.; Taylor, M.D.; Sinha, P.; Calfee, C.S.; Hirayama, A.V.; Mastroiani, F.; Turtle, C.J.; Harhay, M.O.; Legrand, M.; Deutschman, C.S. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med., 2020, 8(12), 1233-1244.
[http://dx.doi.org/10.1016/S2213-2600(20)30404-5] [PMID: 33075298]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy